Changes in serum anti-mullerian hormone level during low-dose recombinant follicular-stimulating hormone therapy for anovulation in polycystic ovary syndrome
- PMID: 17698904
- DOI: 10.1210/jc.2007-0868
Changes in serum anti-mullerian hormone level during low-dose recombinant follicular-stimulating hormone therapy for anovulation in polycystic ovary syndrome
Abstract
Context: We previously hypothesized that the excess of anti-müllerian hormone (AMH) at the level of selectable follicles could be involved in the follicular arrest of polycystic ovary syndrome (PCOS), mainly through inhibition of FSH effect on aromatase expression.
Objective: In this study, we investigated whether a decrease in the serum AMH level was concomitant to the appearance of a dominant follicle induced by administration of mild amounts of exogenous FSH in women with PCOS.
Design: A total of 30 women with PCOS in whom anovulation was resistant to clomiphene citrate received recombinant FSH using the low-dose step-up protocol during only one cycle. Serum levels of estradiol, AMH, LH, FSH, inhibin B, and ultrasound parameters were assessed twice a week until 3 d after the appearance of one or more dominant follicle(s).
Results: The day of dominance (d 0) was defined by the appearance of at least one follicle more than 10 mm growing 2 mm/d. From d -14 before dominance to d +3, the mean serum AMH level and the 2- to 5-mm follicle number at ultrasound declined steadily, although not significantly by ANOVA. Mean AMH relative values (100% being the value at d 0) declined significantly (P = 0.04), from 125 +/- 32% at d -14 to 105 +/- 15% at d -4. Within the same time lag, the mean FSH relative values increased from 91 +/- 17% to 107 +/- 19% (P = 0.013). In the 87 samples obtained from d -14 to -4, absolute values of AMH were positively and negatively associated with those of LH and FSH, respectively, in an independent manner (P = 0.009 and P = 0.03, respectively). In the 55 samples collected at d 0 and +3, they were negatively correlated to those of estradiol (r = -0.272; P < 0.05).
Conclusions: These data suggest that in anovulatory women with PCOS, gently increasing the serum FSH level reduces the AMH excess, thus relieving the inhibition from the latter on aromatase expression by selectable follicles and allowing the emergence of a dominant follicle.
Similar articles
-
Loss of LH-induced down-regulation of anti-Müllerian hormone receptor expression may contribute to anovulation in women with polycystic ovary syndrome.Hum Reprod. 2013 Mar;28(3):762-9. doi: 10.1093/humrep/des460. Epub 2013 Jan 14. Hum Reprod. 2013. PMID: 23321213
-
The relationship between serum anti-Müllerian hormone levels and the follicular arrest for women with polycystic ovary syndrome.Syst Biol Reprod Med. 2015 Apr;61(2):103-9. doi: 10.3109/19396368.2014.973123. Epub 2014 Oct 20. Syst Biol Reprod Med. 2015. PMID: 25329139
-
Anti-Müllerian hormone dynamics during ovulation induction treatment with recombinant follicle-stimulating hormone in women with polycystic ovary syndrome.Endokrynol Pol. 2013;64(3):203-7. Endokrynol Pol. 2013. PMID: 23873424
-
The role of anti-Müllerian hormone in the pathogenesis and pathophysiological characteristics of polycystic ovary syndrome.Eur J Obstet Gynecol Reprod Biol. 2016 Apr;199:82-7. doi: 10.1016/j.ejogrb.2016.01.029. Epub 2016 Feb 10. Eur J Obstet Gynecol Reprod Biol. 2016. PMID: 26914398 Review.
-
Interactions between androgens, FSH, anti-Müllerian hormone and estradiol during folliculogenesis in the human normal and polycystic ovary.Hum Reprod Update. 2016 Nov;22(6):709-724. doi: 10.1093/humupd/dmw027. Epub 2016 Aug 27. Hum Reprod Update. 2016. PMID: 27566840 Review.
Cited by
-
The effect of laparoscopic ovarian drilling in patients with anovulatory polycystic ovary syndrome and high serum levels of anti-Müllerian hormone.J Med Life. 2023 Jul;16(7):1047-1049. doi: 10.25122/jml-2023-0067. J Med Life. 2023. PMID: 37900074 Free PMC article.
-
Role of Anti-Müllerian Hormone in the Pathogenesis of Polycystic Ovary Syndrome.Front Endocrinol (Lausanne). 2020 Sep 9;11:641. doi: 10.3389/fendo.2020.00641. eCollection 2020. Front Endocrinol (Lausanne). 2020. PMID: 33013710 Free PMC article. Review.
-
Serum anti-mullerian hormone concentrations are elevated in oligomenorrheic girls without evidence of hyperandrogenism.J Clin Endocrinol Metab. 2010 Apr;95(4):1786-92. doi: 10.1210/jc.2009-2106. Epub 2010 Feb 11. J Clin Endocrinol Metab. 2010. PMID: 20150576 Free PMC article.
-
Serum levels of anti-Müllerian hormone influence pregnancy outcomes associated with gonadotropin-releasing hormone antagonist treatment: a retrospective cohort study.Sci Rep. 2023 Feb 6;13(1):2127. doi: 10.1038/s41598-023-28724-8. Sci Rep. 2023. PMID: 36746984 Free PMC article.
-
Live birth rate after human chorionic gonadotropin priming in vitro maturation in women with polycystic ovary syndrome.J Ovarian Res. 2018 Aug 27;11(1):70. doi: 10.1186/s13048-018-0445-5. J Ovarian Res. 2018. PMID: 30149808 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical